Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Clark, MD, Kathleen G. Benjamin, RNC, MSN, NNP Echevarria Ybarguengoitia, using bililabstix to prospectively evaluate occult hematochezia in 300 premature newborns, reported a 0.47% incidence of ...

Background. A 48-year-old woman with chronic urinary tract infections presented with uremia. Imaging studies revealed bilateral hydronephrosis and segmental ureteral thickening. Investigations.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ...

Abdominal venous thrombosis is a rare form of venous thromboembolic disease in children. While mortality rates are low, a significant proportion of affected children may suffer long-term morbidity.

Leukemia symptoms can vary by the cancer stage and type of leukemia you have. In the early stages, leukemia symptoms like fatigue, fever, and bruising can be subtle and easily dismissed. But, as the ...

1 Department of Gastric and Colorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China 2 Department of Urology, The First Hospital of Jilin University, ...

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad 382355, Gujarat, India Department of Pharmacology and Toxicology, College of ...

Are problems with your digestive system causing concerns? Explore some of the diseases that may be causing your symptoms and learn how they're treated.